Venous thromboembolism incidence shortens survival in isocitrate dehydrogenase wild-type glioblastoma
Neuro-Oncology Advances · 06.01.2025 · 7 (1)
DOI: 10.1093/noajnl/vdaf018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 31.01.2025. Verfasst von Anthony R Sloan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Case Comprehensive Cancer Center, Cleveland, Ohio, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NHLBI NIH HHS, NCI NIH HHS.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Background
Venous thromboembolisms (VTE’s) are the second leading cause of death in cancer patients. While previous analyses have demonstrated VTE rates are greater in GBM patients using smaller patient cohorts in high-grade glioma, since the release of the update 5 th edition of the World Health Organization (WHO) classification a systematic analysis in a large-scale cohort of patients with IDH-wildtype GBM with clinical outcomes is lacking.
Methods
This study utilizes the online database, TriNetx, to build patient cohorts for outcomes analysis. TriNetX is a database comprised of over 50 healthcare organization patient information that is quarriable by CPT, ICD, RxNorm, and other proprietary codes. Patient cohort demographics were used for propensity score matching. Risk ratios, odds ratios, hazard ratios, and Kaplan Meier curves were utilized for primary outcomes including survival and time-to-event analyses.
Results
24% of patients with GBM experienced at least 1 VTE or PE after their diagnosis. Compared to a population of patients with no cancer history with an index event of an inpatient visit, patients with GBM were at 20.4 (12.23-34.17) and 5.96 (3.85-9.23) times higher risk of experiencing a VTE/PE at 1- and 5-year follow-up, respectively. Sex differences were not seen between VTE/PE rates and survival after VTE/PE at 1- and 5-year follow-up (p>0.05). Lastly, patients with GBM and a VTE/PE after diagnosis experienced worse survival at 1- and 5-year follow-up compared to those without a VTE/PE (p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Case Comprehensive Cancer Center, Cleveland, Ohio, USA.
- Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
- Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
- Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Pathology, Northwestern University, Chicago, Illinois, USA.
ORCID-Profile: Anthony R Sloan, Craig Horbinski, David C Kaelber, Scott J Cameron, Justin D Lathia
Förderung
- NINDS NIH HHS
- NHLBI NIH HHS
- NCI NIH HHS
- Cancer Biology Training
- Ruth L. Kirschstein Postdoctoral NRSA
- Midwest Brain Tumor Foundation Postdoctoral Fellowship
- Lerner Research Institute
- Case Comprehensive Cancer Center
Zitieren
APA
Sloan, A. R., Gordillo, A. J., Kennemer, A., Khorana, A. A., Horbinski, C., Kaelber, D. C., Cameron, S. J., & Lathia, J. D. (2025). Venous thromboembolism incidence shortens survival in isocitrate dehydrogenase wild-type glioblastoma. Neuro-Oncology Advances, 7(1). https://doi.org/10.1093/noajnl/vdaf018
Vancouver
Sloan AR, Gordillo AJ, Kennemer A, Khorana AA, Horbinski C, Kaelber DC, et al. Venous thromboembolism incidence shortens survival in isocitrate dehydrogenase wild-type glioblastoma. Neuro-Oncology Advances. 2025;7(1). doi:10.1093/noajnl/vdaf018
BibTeX
@article{Sloan2025,
author = {Sloan, Anthony R and Gordillo, Alan J and Kennemer, Austin and Khorana, Alok A and Horbinski, Craig and Kaelber, David C and Cameron, Scott J and Lathia, Justin D},
title = {Venous thromboembolism incidence shortens survival in isocitrate dehydrogenase wild-type glioblastoma},
journal = {Neuro-Oncology Advances},
year = {2025},
volume = {7},
number = {1},
doi = {10.1093/noajnl/vdaf018}
}
EUVIMED